Home・Elenco Azioni・TransMedics Group Inc

TransMedics Group Inc

Chiusa

SettoreSettore sanitario

80.5 -1.38

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

78.31

Massimo

81.92

Metriche Chiave
By Trading Economics
Entrata	-98M 7.3M
Vendite	13M 174M
P/E Media del settore	16.998 64.641
EPS	0.3
Margine di Profitto	4.206
Dipendenti	898
EBITDA	-4.9M 28M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+41.02% upside

Dividendi
By Acuity
Utili prossimi	4 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-786M 2.6B
Apertura precedente	81.88
Chiusura precedente	80.5

Notizie sul Sentiment di mercato

By Acuity

65%

35%

289 / 340 Classifica in Healthcare

TransMedics Group Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 ago 2026, 19:51 UTC

Social Media

News

TransMedics Group Inc. shares are rising, despite an analyst downgrade to a $106 price target from $142, amid positive social media discussions.

30 lug 2026, 19:03 UTC

Transmedics Group Inc shares are lower during Thursday's session, with no specific news identified. Broader market uncertainty may be influencing the decline.

29 lug 2026, 23:36 UTC

Transmedics Group Inc. shares are lower in after-market trading, reflecting broader market volatility amid rising interest rates and geopolitical tensions.

28 lug 2026, 19:46 UTC

Transmedics Group Inc shares are higher today, advancing since Monday. The stock peaked earlier but pulled back from a session high.

27 lug 2026, 15:16 UTC

Social Media

News

Transmedics Group Inc is higher today amid social media discussions on its undervaluation and expectations for significant profit by 2028.

24 lug 2026, 20:02 UTC

Social Media

Transmedics Group Inc gains amid positive feedback from Jefferies on its technology and growth prospects, aligning with strength in the Health Care Equipment sector.

22 lug 2026, 19:46 UTC

Transmedics Group Inc shares are lower today, reflecting ongoing declines. The stock's volatility coincides with rising crude oil prices amid geopolitical tensions.

21 lug 2026, 14:36 UTC

Social Media

Transmedics Group's shares are higher today following the first lung transplant using its OCS warm-perfusion device, enhancing organ preservation and clinical outcomes.

20 lug 2026, 12:26 UTC

Social Media

TransMedics Group Inc shares are higher in pre-market trading amid strong operational growth, with flights exceeding 36 per day and projected revenue of $3 billion by 2032.

Confronto tra pari

Modifica del prezzo

TransMedics Group Inc Previsione

Obiettivo di Prezzo

By TipRanks

41.02% in crescita

Previsioni per 12 mesi

Media 115 USD 41.02%

Alto 175 USD

Basso 80 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per TransMedics Group Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

10 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 10 che hanno fornito valutazioni azionarie a TransMedics Group Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

289 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.